Evidence map›Paper›PMID 25135999›Full record

ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2015

Strength and function response to clinical interventions of older women categorized by weakness and low lean mass using classifications from the Foundation for the National Institute of Health sarcopenia project.

Maren S Fragala, Thuy-Tien L Dam, Vanessa Barber, James O Judge, Stephanie A Studenski, Peggy M Cawthon, Robert R McLean, Tamara B Harris, Luigi Ferrucci, Jack M Guralnik and 5 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03574662 (A Prospective Trial to Evaluate the Utility of Focused Frailty Interventions on Patients With Advanced Heart Failure), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03574662 nacompletednot on this mapstarted 2018, after this paper: background citation

A Prospective Trial to Evaluate the Utility of Focused Frailty Interventions on Patients With Advanced Heart Failure

TypeinterventionalSponsorMayo ClinicRan2018 to 2018Enrolled1ConditionsHeart FailureArmsFrailty assessment, Quality of life assessment
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography: A Systematic Review.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019
    Pooled it
  3. Trial
  4. Review
  5. Article
  6. The Association of Neighborhood Characteristics and Frailty in Childhood Cancer Survivors: A Report from the St. Jude Lifetime Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  7. Sarcopenia in Menopausal Women: Current Perspectives.International journal of women's health · 2022
    Review
  8. Review
  9. Screening for Sarcopenia (Physical Frailty) in the COVID-19 Era.International journal of endocrinology · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Frailty phenotypes and mortality after lung transplantation: A prospective cohort study.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2018
    Article
  14. Review
  15. Physical Therapy Considerations for Chronic Kidney Disease and Secondary Sarcopenia.Journal of functional morphology and kinesiology · 2018
    Article
  16. Review
  17. Article
  18. Article
  19. Sarcopenia and the New ICD-10-CM Code: Screening, Staging, and Diagnosis Considerations.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Maren S FragalaUniversity of Central Florida, Orlando.
Thuy-Tien L DamColumbia University College of Physicians and Surgeons, New York.
Vanessa BarberUniversity of Connecticut Health Center, Farmington.
James O JudgeUniversity of Connecticut Health Center, Farmington.
Stephanie A StudenskiNational Institute of Aging, National Institutes of Health, Bethesda, Maryland.
Peggy M CawthonCalifornia Pacific Medical Center Research Institute, San Francisco.
Robert R McLeanHebrew Senior Life Institute for Aging Research, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Tamara B HarrisNational Institute of Aging, National Institutes of Health, Bethesda, Maryland.
Luigi FerrucciNational Institute of Aging, National Institutes of Health, Bethesda, Maryland.
Jack M GuralnikUniversity of Maryland School of Medicine, Baltimore.
Douglas P KielHebrew Senior Life Institute for Aging Research, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Stephen B KritchevskyWake Forest University School of Medicine, Winston-Salem, North Carolina.
Michelle D ShardellUniversity of Maryland School of Medicine, Baltimore.
Maria T VassilevaFoundation for the National Institutes of Health, Bethesda, Maryland.
Anne M KennyUniversity of Connecticut Health Center, Farmington. kenny@uchc.edu.
National Institutes of Health · USUConn Health · USUniversity of Maryland, Baltimore · USCalifornia Pacific Medical Center · USColumbia University · USFoundation for the National Institutes of Health · USHarvard University · USHebrew SeniorLife · USUniversity of Central Florida · USWake Forest University · US

Funding

ZONISAMIDE VERSUS PLACEBOM01RR006192 · NCRR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI DRAZINIC, CAROLYN M · 1994 to 2008
$22.1M
CLINICAL PROJECT: Age, Gene/Environment Susceptibility Study on the Multi-omics of Aging: A clinical epidemiologic prospective studyZIAAG007380 · NIA · NATIONAL INSTITUTE ON AGING · PI LAUNER, LENORE J · 2009 to 2025
$6.1M
Health, Aging and Body Composition StudyZIAAG007390 · NIA · NATIONAL INSTITUTE ON AGING · PI LAUNER, LENORE J · 2009 to 2024
$4.0M
HORMONE REPLACEMENT THERAPY ON BONE TURNOVER AND DENSITY IN OLDER WOMENP60AG013631 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI BESDINE, RICHARD W · 1996 to 2002
$2.2M
TESTOSTERONE THERAPY FOR MEN WITH OSTEOPOROSISR01AG018887 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KENNY, ANNE M · 2001 to 2005
$1.8M
Sarcopenia analysis in NHANESZIAAG004050 · NIA · NATIONAL INSTITUTE ON AGING · PI HARRIS, TAMARA · 2009 to 2014
$620k
NCRR NIH HHS M01 RR006192NCRR NIH HHS MO1-RR06192NIA NIH HHS 5P60AG13631NIA NIH HHS R01 AG018887NIA NIH HHS R01-AG18887
6 · The paper itself

Abstract

backgroundThe Foundation for the National Institutes of Health Sarcopenia Project developed data-driven cut-points for clinically meaningful weakness and low lean body mass. This analysis describes strength and function response to interventions based on these classifications.

methodsIn data from four intervention studies, 378 postmenopausal women with baseline and 6-month data were evaluated for change in grip strength, appendicular lean mass corrected for body mass index, leg strength and power, and short physical performance battery (SPPB). Clinical interventions included hormones, exercise, and nutritional supplementation. Differences in outcomes were evaluated between (i) those with and without weakness and (ii) those with weakness and low lean mass or with one but not the other. We stratified analyses by slowness (walking speed ≤ 0.8 m/s) and by treatment assignment.

resultsThe women (72±7 years; body mass index of 26±5kg/m(2)) were weak (33%), had low lean mass (14%), or both (6%). Those with weakness increased grip strength, lost less leg power, and gained SPPB score (p < .05) compared with nonweak participants. Stratified analyses were similar for grip strength and SPPB. With lean mass in the analysis, individuals with weakness had larger gains in grip strength and SPPB scores regardless of low lean mass (p < .01).

conclusionsOlder women with clinically meaningful muscle weakness increased grip strength and SPPB, regardless of the presence of low lean mass following treatment with interventions for frailty. Thus, results suggest that muscle weakness, as defined by the Foundation for the National Institutes of Health Sarcopenia Project, appears to be a treatable symptom.

Indexed as

Absorptiometry, PhotonAdjuvants, ImmunologicAgedBody CompositionBone Density Conservation AgentsCalcium CitrateDehydroepiandrosteroneDisease SusceptibilityEstradiolEstrogen Replacement TherapyEstrogensFemaleFish OilsGaitHumansMiddle AgedAdjuvants, ImmunologicBone Density Conservation AgentsCalcium CitrateDehydroepiandrosteroneEstradiolEstrogensFish OilsVitamin DClinical trials.FunctionGait speedSarcopeniaStrength

Identifiers

PMID25135999
PMCPMC4311186
OpenAlexW2162185734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.